Following up on our findings that chaetocin cooperates with Bcl2/BclXL inhibitors (Fig. 3e–l), we further examined whether genetic manipulation of Bcl2 and/or BclXL could change the chaetocin-mediated TRAIL sensitization in GBM cells. The gene discussed is BCL2L1; the disease is glioblastoma.